Conductive silk–polypyrrole composite scaffolds with bioinspired nanotopographic cues for cardiac tissue engineering

Tsui, Jonathan H.; Ostrovsky-Snider, Nicholas; Yama, David Michael Patrick; Donohue, Jordan D.; Choi, Jong Seob; Chavanachat, Rakchanok; Larson, Jesse D.; Murphy, Ana A.; Kim, Deok Ho

doi:10.1039/c8tb01116h

Cited by 91 publications

(64 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiac scaffolds have been made from electro-conductive acid-modified silk fibroinpoly (pyrrole) substrates. With PSC derived cardiomyocytes these grafts showed enhanced gap junction distribution and cardiomyocyte maturation [33,34] .…”

Section: Engineered Tissue To Treat Heart Failurementioning

confidence: 96%

See 1 more Smart Citation

Surgical treatment for heart failure: cell-based therapy with engineered tissue

Lancaster

Koevary

Chinyere

et al. 2019

View full text Add to dashboard Cite

This review will outline cell-based therapy for heart failure focusing on tissue engineering to deliver cells to the damaged heart. We will present an overview of the central approaches focusing on pluripotent stem cell-derived cells, mechanisms of action, autologous vs. allogeneic cell approaches, immunologic modulation, and safety considerations. We will outline the progress that has been made to-date and define the areas that still need to be investigated in order to advance the field.

show abstract

Section: Engineered Tissue To Treat Heart Failurementioning

confidence: 96%

“…[32] PSC-CMs Allo Silk fibrion-poly (pyrrole) Pre-clinical Tsui et al . [33] PSC-CMs Allo Cell sheets Pre-clinical Matsuura et al . [46] PSC-CMs Allo Cell Sheets Pre-clinical Sasagawa et al .…”

Section: Mechanisms Of Action Of Cell-based Therapymentioning

confidence: 99%

Surgical treatment for heart failure: cell-based therapy with engineered tissue

Lancaster

Koevary

Chinyere

et al. 2019

View full text Add to dashboard Cite

show abstract

“…PPy can be used for creating conductive and biocompatible scaffold for tissue simulations like cultured human pluripotent stem cells (hPSC)‐derived cardiomyocytes on silk fibroin‐poly(pyrrole), Schwann cells (S42) rat pheochromocytoma cells (PC12) on chitosan‐MVCN‐PPy double‐layered nerve guidance conduit (NGC) and smooth muscle cells (SMCs) on PPy‐coated Poly (trimethylene carbonate) scaffolds …”

Section: Introductionmentioning

confidence: 99%

Polycaprolactone‐chitosan‐polypyrrole conductive biocomposite nanofibrous scaffold for biomedical applications

2019

View full text Add to dashboard Cite

In this study, polycaprolactone/chitosan/polypyrrole (PCL/chitosan/PPy) conductive composite nanofibrous scaffold is fabricated. For this purpose, initially, a polymer blend of PCL/chitosan (7:3) and (4:1) was selected and then 1, 2.5, 5 and 7.5 wt% of PPy was added to each solution. A range of techniques were applied to study the chemical, physical and biodegradability properties of the resultant fibrous mats. According to scanning electron microscope (SEM) images, with the addition of PPy to the PCL/chitosan blend, the size of the fiber diameter decrease. There was significant increase in the electrical conductivity of the mats such that the electrical conductivity of PCL/chitosan was around 0.1 S/cm but increased to 2 S/cm in biological environment with the addition of 7.5% PPy. Hydrophobicity was found to improve with the addition of PPy as water contact angle changed from 120 ± 10 for PCL/chitosan to 133 ± 18 at 7.5% PPy. The incorporation of PPy within the PCL/chitosan matrix was found to positively influence the overall properties of nanofibrous structure, making them suitable for biomedical applications.

show abstract

“…The literature reveals that in the last few years, there has been an increasing interest in the development of silk-based scaffold materials (234)(235)(236)(237)(238)(239)(240)(241)(242)(243). For example, Tsui et al (234) produced electroconductive acid-modified silk fibroin-poly(pyrrole) (AMSF + PPy) scaffolds patterned with nanoscale ridges to enhance structural and functional properties of cultured human pluripotent stem cell (hPSC)-derived cardiomyocytes (234) ( Figure 8C). The authors reported an enhanced organization of cardiomyocytes, in vitro, exhibiting improved sarcomere and gap junction development as well as increased expression of genes that are part of the control for cardiac tissue excitation and contraction functions.…”

Section: Silk As a Scaffold Biomaterials For Cardiac Tissue Repairmentioning

confidence: 99%

Natural Biomaterials for Cardiac Tissue Engineering: A Highly Biocompatible Solution

Majid

Fricker

Gregory

et al. 2020

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) constitute a major fraction of the current major global diseases and lead to about 30% of the deaths, i.e., 17.9 million deaths per year. CVD include coronary artery disease (CAD), myocardial infarction (MI), arrhythmias, heart failure, heart valve diseases, congenital heart disease, and cardiomyopathy. Cardiac Tissue Engineering (CTE) aims to address these conditions, the overall goal being the efficient regeneration of diseased cardiac tissue using an ideal combination of biomaterials and cells. Various cells have thus far been utilized in pre-clinical studies for CTE. These include adult stem cell populations (mesenchymal stem cells) and pluripotent stem cells (including autologous human induced pluripotent stem cells or allogenic human embryonic stem cells) with the latter undergoing differentiation to form functional cardiac cells. The ideal biomaterial for cardiac tissue engineering needs to have suitable material properties with the ability to support efficient attachment, growth, and differentiation of the cardiac cells, leading to the formation of functional cardiac tissue. In this review, we have focused on the use of biomaterials of natural origin for CTE. Natural biomaterials are generally known to be highly biocompatible and in addition are sustainable in nature. We have focused on those that have been widely explored in CTE and describe the original work and the current state of art. These include fibrinogen (in the context of Engineered Heart Tissue, EHT), collagen, alginate, silk, and Polyhydroxyalkanoates (PHAs). Amongst these, fibrinogen, collagen, alginate, and silk are isolated from natural sources whereas PHAs are produced via bacterial fermentation. Overall, these biomaterials have proven to be highly promising, displaying robust biocompatibility and, when combined with cells, an ability to enhance post-MI cardiac function in pre-clinical models. As such, CTE has great potential for future clinical solutions and hence can lead to a considerable reduction in mortality rates due to CVD.

show abstract

Conductive silk–polypyrrole composite scaffolds with bioinspired nanotopographic cues for cardiac tissue engineering

Cited by 91 publications

References 80 publications

Surgical treatment for heart failure: cell-based therapy with engineered tissue

Surgical treatment for heart failure: cell-based therapy with engineered tissue

Polycaprolactone‐chitosan‐polypyrrole conductive biocomposite nanofibrous scaffold for biomedical applications

Natural Biomaterials for Cardiac Tissue Engineering: A Highly Biocompatible Solution

Contact Info

Product

Resources

About